We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCIR
RNS Number : 6058N
Circassia Group Plc
30 September 2021
Circassia Group plc
Block Listing Interim Review
Oxford, UK - 30 September 2021: Circassia Group plc (LSE: CIR), a medical device company focused on point of care asthma diagnosis and management, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of the company: Circassia Group plc Name of relevant scheme: 1) Circassia EMI Share Option Scheme 2) Circassia 2007 Unapproved Share Scheme 3) Circassia 2014 Performance Share Plan Scheme 4) Circassia 2015 Performance Share Plan Scheme 5) Circassia 2016 Performance Share Plan Scheme 6) Circassia 2017 Performance Share Plan Scheme 7) Circassia 2020 Save As You Earn Scheme (UK) ---------------------------------------- Period of return: From: 1 April 2021 To: 30 September 2021 --------- -------------- --- ------------------- Balance of unallotted securities 1) 700,750 under scheme(s) from previous 2) 203,000 return: 3) 76,676 4) 238,019 5) 709,543 6) 397,296 7) 0 Total 2,325,284 ---------------------------------------- Plus: The amount by which the 1) - 6) inclusive: Nil block scheme(s) has been increased 7) 1,141,658 since the date of the last return (if any increase has been applied for): ---------------------------------------- Less: Number of securities issued/allotted 1) - 3) inclusive: Nil under scheme(s) during period: 4) (65,297) 5) (128,617) 6) (346,624) 7) (14,765) Total (555,303) ---------------------------------------- Equals: Balance under scheme(s) 1) 700,750 not yet issued/allotted at end 2) 203,000 of period: 3) 76,676 4) 172,722 5) 580,926 6) 50,672 7) 1,126,893 Total 2,911,639 ---------------------------------------- Number and class of securities 1) 2,600,000 - 20 March 2014 originally listed and the date 2) 516,000 - 1 June 2017 of admission: 3) 500,000 - 1 June 2017 4) 400,000 - 21 May 2018 5) 930,000 - 1 July 2019 6) 980,000 - 22 May 2020 7) 1,141,658 - 1 April 2021 ---------------------------------------- Name of contact: Sarah Duncan Telephone number of contact: 01865 405 560 -------------
For further information, please contact:
Singer Capital Markets (Nominated Adviser Tel: +44 (0) 20 7496 and Broker) 3000 Aubrey Powell / Jen Boorer / Hannah Woodley ----------------------------------------- --------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRMZGFLDGZGMZM
(END) Dow Jones Newswires
September 30, 2021 10:15 ET (14:15 GMT)
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions